Abiopharma

Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines

(85% Positive) Onconova Therapeutics Inc. (was merged with Trawsfynydd Therapeutics, Inc. on 02/04/2024) (ONTX) Files Form 8-K

Sono-Tek Reports Fiscal Third Quarter and Nine-Month Fiscal 2026 Financial Results

Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data

Energous Reports Preliminary Financial Results for Fiscal Year 2025, Marking a Transformational Year of Growth and Platform Expansion

Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus

Labcorp Expands MRD Testing for Breast, Lung and Colon Cancer Recurrence Risk

Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients

New Form 425 - WATERS CORP /DE/ Filed: 2026-01-13 AccNo: 0001193125-26-011092 Size: 75 KB

SciSparc Notification (SPRC)

SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity

(85% Positive) Cardinal Health Inc (CAH) Reports Q1 2026 Financial Results

BD Announces $110 Million to Support U.S. Pharmaceutical Supply Chain for Biologic Drugs

Cardinal Health Raises Fiscal 2026 Outlook and Highlights Strategic Progress During J.P. Morgan Healthcare Conference Presentation